The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013. The most important elements were: TK: expansion in the US of the pivotal Phase III trial for high-risk leukaemia patients; NGR-TNF: continuation of the clinical development program; the increase of revenues […]
MolMed expands in the United States the Phase III trial of TK for the treatment of high-risk leukaemia
MolMed announces the enrolment of the first patient in the United States, initiating the cross-Atlantic expansion of the pivotal Phase III trial (TK008) of its proprietary TK cell/gene therapy for high-risk leukaemia patients. The study, already ongoing in Europe, foresees patient enrolment in 16 clinical centres worldwide. Claudio Bordignon, Chairman of the Board and CEO […]
MolMed, new data on NGR-hTNF: significant survival increase in sarcomas
MolMed, new data presented at the European Cancer Congress show a statistically significant increase in survival of patients suffering from soft tissue sarcomas treated with NGR-hTNF. MolMed S.p.A. (MLM.MI) presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), in Amsterdam (The Netherlands), additional data from an ongoing randomized Phase II study evaluating safety […]
European Cancer Congress, MolMed on efficacy of drug NGR-hTNF
MolMed S.p.A. will present further data on the efficacy of the investigational drug NGR-hTNF in soft tissues sarcomas tomorrow at the European Cancer Congress. MolMed S.p.A. (MLM.MI) will present further data on the efficacy of its investigational drug NGR-hTNF in combination with doxorubicin in soft tissue sarcomas, tomorrow at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) taking […]
MolMed, Outcome of Shareholders’ meeting and meeting of Board of Directors
MolMed Shareholders’ Meeting confirms the appointment of a Member of the Board and approves Measures to be adopted pursuant to Article 2446 of the Italian Civil Code. Meeting of the Board of Directors: Professor Riccardo Cortese appointed as member of the Remuneration committee. Shareholders’ Meeting The Shareholders’ Meeting of MolMed S.p.A. (MLM.MI), chaired […]
MolMed official notification from the European Patent Office for NGR-hTNF
MolMed S.p.A. (MLM.MI) announces today receipt of the official notification from the European Patent Office of the decision to grant a patent covering the therapeutic use of its investigational anticancer drug NGR-hTNF at low doses. The grant will take effect on the 2nd of October 2013, when it will be published in the European Patent […]